GI Dynamics

GI DynamicsGI Dynamics
GI Dynamics

GI Dynamics

Develops a minimally invasive implantable device for treating type 2 diabetes and obesity.

DR 31Speed 552005Active57Lexington, United States
Rate

About

GI Dynamics is a medical device company focused on developing and commercializing the EndoBarrier Gastrointestinal Liner, a novel, implantable device designed for the treatment of type 2 diabetes and obesity. The EndoBarrier is a flexible, tube-shaped liner that is endoscopically implanted into the small intestine, creating a barrier between food and the intestinal wall to improve metabolic health.
Frequently asked

What does GI Dynamics do?

GI Dynamics is a medical device company focused on developing and commercializing the EndoBarrier Gastrointestinal Liner, a novel, implantable device designed for the treatment of type 2 diabetes and obesity. The EndoBarrier is a flexible, tube-shaped liner that is endoscopically implanted into the small intestine, creating a barrier between food and the intestinal wall to improve metabolic health.

What is GI Dynamics's revenue?

StartupHub estimates GI Dynamics's annual revenue at $14.8M (range $4.7M to $53.6M, 27% confidence), based on comparable companies in the sector.

What is GI Dynamics's valuation?

StartupHub estimates GI Dynamics's effective valuation at $533.0M (range $325.0M to $780.0M, 10% confidence), based on comparable companies in the sector.

How much funding has GI Dynamics raised?

GI Dynamics has raised a total of $130M in funding. The most recent round on record is Series D.

Where is GI Dynamics headquartered?

GI Dynamics is headquartered in Lexington, United States.

When was GI Dynamics founded?

GI Dynamics was founded in 2005.

What industry does GI Dynamics operate in?

GI Dynamics operates in MedTech, HealthTech, Medical Devices, Diabetes Treatment, Obesity Treatment, Minimally Invasive Surgery.

How many employees does GI Dynamics have?

GI Dynamics has approximately 57 people on record.

HEADCOUNT
57
DOMAIN RATING
31
Comments

No comments yet. Be the first to share your take.